Victory Capital Management Inc. Has $5.89 Million Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Victory Capital Management Inc. increased its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 1,729.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 130,797 shares of the company’s stock after acquiring an additional 123,647 shares during the period. Victory Capital Management Inc. owned about 0.22% of Protagonist Therapeutics worth $5,886,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC raised its stake in shares of Protagonist Therapeutics by 749.2% during the 3rd quarter. GAMMA Investing LLC now owns 552 shares of the company’s stock worth $25,000 after purchasing an additional 487 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in Protagonist Therapeutics in the first quarter valued at approximately $35,000. Exchange Traded Concepts LLC bought a new stake in Protagonist Therapeutics in the third quarter worth approximately $43,000. CWM LLC increased its stake in shares of Protagonist Therapeutics by 910.3% during the 3rd quarter. CWM LLC now owns 1,273 shares of the company’s stock worth $57,000 after purchasing an additional 1,147 shares during the last quarter. Finally, Lazard Asset Management LLC bought a new position in shares of Protagonist Therapeutics during the 1st quarter valued at $69,000. Institutional investors and hedge funds own 98.63% of the company’s stock.

Protagonist Therapeutics Stock Up 11.5 %

Shares of NASDAQ PTGX opened at $46.46 on Friday. Protagonist Therapeutics, Inc. has a 12 month low of $16.80 and a 12 month high of $48.89. The company has a market cap of $2.77 billion, a P/E ratio of 17.82 and a beta of 2.17. The business’s 50 day moving average is $45.26 and its two-hundred day moving average is $39.02.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on PTGX shares. JMP Securities decreased their price objective on shares of Protagonist Therapeutics from $45.00 to $43.00 and set a “market outperform” rating for the company in a report on Wednesday, August 7th. StockNews.com upgraded Protagonist Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Protagonist Therapeutics in a research note on Tuesday. Wedbush reaffirmed an “outperform” rating and set a $58.00 target price on shares of Protagonist Therapeutics in a research report on Tuesday. Finally, Truist Financial initiated coverage on Protagonist Therapeutics in a report on Monday, September 9th. They set a “buy” rating and a $60.00 price target on the stock. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Protagonist Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $53.57.

Insider Transactions at Protagonist Therapeutics

In related news, insider Arturo Md Molina sold 1,906 shares of the stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $40.98, for a total value of $78,107.88. Following the completion of the sale, the insider now owns 46,444 shares in the company, valued at approximately $1,903,275.12. This trade represents a 3.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Asif Ali sold 14,203 shares of the business’s stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $44.49, for a total value of $631,891.47. Following the transaction, the chief financial officer now owns 34,960 shares in the company, valued at $1,555,370.40. This represents a 28.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 24,109 shares of company stock worth $1,069,999. Insiders own 5.40% of the company’s stock.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.